Definitely, the possibility of establishing the relationship between the cellular burden and the transcript load could better clarify the mechanisms that regulate the transcription clearance kinetic during TKIs treatment, allowing the early detection of CML patients who will not achieve an optimal treatment response at the third month of therapy (i.e. BCR-ABL1IS ≥10%). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.